TP53 and acute myeloid leukemia: Potential therapeutic target in AML.PLK4 is overexpressed in the TP53-mutant AML subtype and its inhibition induces antileukemic effects [91].Downregulation of PLK4 induces cell apoptosis and G2/M arrest in AML [92].